Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a
dismal prognosis, with only modest advances in therapeutic strategies over the past several …

Lung cancer has a significant incidence among the population and, unfortunately, has an
unfavourable prognosis in most cases. The World Health Organization (WHO) classifies lung …

T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising
immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate …

Simple Summary Small cell lung cancer (SCLC) remains a difficult-to-treat disease and is
associated with a poor prognosis in most patients. Discovering biomarkers and developing …

Introduction Small cell transformation (SCT) is a typical mechanism of adaptive resistance to
third generation epidermal growth factor receptor inhibitors (EGFRi) which have become the …

Background We explored potential predictive biomarkers of immunotherapy response in
patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab …

Platinum-based chemotherapy plus PD-1 axis blockade is the standard of care in the front-
line treatment of extensive-stage small cell lung cancer (ES-SCLC). Despite the robust and …

DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by
ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC …

Neuroendocrine neoplasms (NENs) represent a diagnostic and therapeutic challenge, due
to their heterogeneity and limited treatment options. Conventional imaging techniques and …

Simple Summary The developments of radioligand therapy, immunotherapy, and targeted
chemotherapy have led to dozens of clinical trials targeting tumor-associated surface …